A groundbreaking study led by Prof. Dimitrios Karussis, head of the Hadassah Medical Organization’s Multiple Sclerosis Center, shows positive effects of NG01, an innovative autologous stem cell therapy, for patients with Amyotrophic Lateral Sclerosis (ALS).
Published in the Journal of Neurology & Neurosurgery, the study examined 20 ALS patients through three clinical trials over a span of 15 years and revealed promising long-term survival outcomes. Patients who received NG01 therapy achieved a median survival of 7.2 years, with 45 percent (9 out of 20) surviving beyond 10 years post-diagnosis, and one patient still alive after 12 years.
The therapy “induces neuro-regeneration and remyelination and repair, which may lead to amelioration of the neurodegeneration that is caused by ALS,” a progressive neurodegenerative disorder that leads to the degeneration of the cells responsible for controlling voluntary movements such as walking, speaking and breathing.
"This study provides compelling indications that NG01 therapies can extend survival in ALS patients, even those with traditionally poor prognostic indicators," said Prof. Karussis in a press release. "Our findings pave the way for larger clinical trials to validate these results and refine treatment protocols."
